Latest Breaking News On - Inborn errors - Page 17 : comparemela.com

Poxel SA: Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases

POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis

France generalUnited statesSouth koreaNoord hollandSumitomo dainippon pharmaMarie curieMarc engelenS ali fatemiStephan kempArthur rouillKeith van harenFanny mochelVan harenFlorian eichlerJaspreet singhCatherine david

Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases

Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesSouth koreaNoord hollandSumitomo dainippon pharmaMarie curieMarc engelenS ali fatemiStephan kempArthur rouillKeith van harenFanny mochelVan harenFlorian eichlerJaspreet singhCatherine david

Ultragenyx Reports Additional Positive Durability Data from AAV Gene Therapy Studies

Ultragenyx Reports Additional Positive Durability Data from AAV Gene Therapy Studies
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesEric crombezInternational congressOrnithine transcarbamylaseInborn errorsUltragenyx geneOrphan drugRegenerative medicine advanced therapyFast track

Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618

/PRNewswire/ Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced.

United kingdomNew south walesAoife brennanJerry vockleyInternational congressPrnewswire synlogic incSynlogic incInborn errorsMetabolism meetingMedical geneticsSynthetic bioticSynlogic presidentChief executiveSynthetic bioticsPrivate securities litigation reform act

Paradigm Biopharmaceuticals Ltd to present positive data from phase 2 rare disease trial at international congress

PPS was well tolerated with no serious adverse events reported over a 24-week period and there were meaningful improvements in pain, function.

New south walesSouth australiaMichael imperialeDonna skerrettDrago bratkovicParadigm biopharmaceuticals ltdInternational congressInborn errorsMetabolic unitAdelaide womenAccess scheme